Core Insights - Healthcare and biotechnology stocks experienced significant movements in after-hours trading, with several companies showing strong gains despite limited news flow [1] Company Summaries - Novo Nordisk A/S (NVO) saw a notable increase of 9.48%, closing at $52.66, following FDA approval of its Wegovy pill, the first oral GLP-1 medicine for obesity in the U.S., which is also approved to reduce cardiovascular risks [2] - Neumora Therapeutics, Inc. (NMRA) advanced 16.02% to $2.10, indicating investor interest possibly driven by broader sector momentum or speculative trading, as there were no specific news updates [3] - BioRestorative Therapies, Inc. (BRTX) rose 6.90% to $1.24, with investors reacting to a prior announcement regarding an FDA Type B meeting to discuss a potential accelerated BLA pathway for its BRTX-100 program for chronic lumbar disc disease [4] - RenovoRx, Inc. (RNXT) added 4.44% to close at $0.94, with earlier news of an accepted abstract submission for the ASCO Gastrointestinal Cancers Symposium 2026 contributing to investor interest [5] - IDEAYA Biosciences, Inc. (IDYA) gained 6.49% to $37.81, following the full enrollment of 435 patients in its Phase 2/3 trial for darovasertib, with expected data reporting in Q1 2026 [6] - Healthcare Triangle, Inc. (HCTI) climbed 6.72% to $1.43, with a recent announcement of an Advance Agreement for acquiring AI-powered customer experience firms, enhancing its position in global AI-driven solutions [7] - Alphatec Holdings, Inc. (ATEC) posted a modest gain of 2.80%, rising to $21.28, benefiting from ongoing investor confidence in the spine surgery provider [8]

Core Viewpoint - Healthcare Triangle, Inc. is acquiring Teyame AI LLC and its subsidiaries, enhancing its position in AI-powered customer and patient engagement solutions [1][2][3] Financial Overview - The total consideration for the acquisition is expected to be approximately $50 million, comprising cash, common stock, non-voting convertible preferred stock, and contingent earnout-based equity [2] - The acquisition is projected to generate about $34 million in incremental annual revenue and $4.2 million in incremental EBITDA for fiscal year 2025 [3] Strategic Importance - This acquisition marks a significant transition for Healthcare Triangle from a healthcare IT provider to a comprehensive digital health innovator, aiming to enhance financial performance and shareholder value [3] - The integration of AI-powered engagement platforms with existing healthcare technologies is expected to create an intelligent ecosystem for patients and providers [5] Technological Advancements - The acquired assets include advanced AI capabilities such as chatbot automation, multilingual patient engagement tools, and real-time analytics, which will enhance HCTI's clinical systems [8][10] - The transaction aims to leverage Agentic Generative AI to improve operational efficiency and drive innovation in healthcare services [4][10] Market Positioning - The acquisition positions Healthcare Triangle as a global leader in AI-powered customer experience solutions, targeting high-growth international markets [7]

Core Viewpoint - Healthcare Triangle, Inc. has entered into a Sales Agreement with Spartan Capital Securities for an at-the-market offering program, allowing the company to raise up to $20 million through the sale of its common stock [1][2]. Group 1: Sales Agreement Details - The Sales Agreement was executed on November 18, 2025, enabling Healthcare Triangle to offer and sell shares with an aggregate market value of up to $20 million [2]. - Shares may be sold on the Nasdaq Capital Market or other trading venues at prevailing market prices, providing flexible access to capital for the company's operational and financial strategy [2]. Group 2: Company Focus and Support - Healthcare Triangle is focused on strengthening its platform and expanding capabilities in cloud-based healthcare solutions [3]. - Spartan Capital Securities expresses support for Healthcare Triangle through the ATM program, indicating a commitment to the company's capital markets initiatives [3]. Group 3: Regulatory Compliance - The shares offered under the ATM program will be issued pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-40903 HEALTHCARE TRIANGLE, INC. (Exact name of registrant as specified in its charter) | Delaware | 84-3559776 | | ...

PLEASANTON, CA / ACCESS Newswire / October 14, 2025 / The market always appreciates a great company story. The problem is that it often rewards the ones that sound big, not necessarily the ones that are big. ...

Core Insights - Healthcare Triangle Inc. has announced a significant growth strategy, indicating a proactive approach to expanding its market presence [1] Company Summary - The company is positioned in the healthcare sector and is focusing on aggressive growth initiatives, which may suggest a shift in its operational strategy [1]

Core Insights - Healthcare Triangle, Inc. (HCTI) is experiencing significant momentum in the AI-powered healthcare technology sector, highlighted by two major developments that position the company for substantial revenue growth and recurring revenue streams [1][3][17] Group 1: Strategic Developments - HCTI signed a Letter of Intent to acquire Teyame.AI, which is expected to generate approximately $34 million in incremental annual revenue and $4.2 million in EBITDA [2][4][17] - The acquisition of Teyame.AI enhances HCTI's capabilities in AI-powered patient engagement, addressing the gap between advanced clinical systems and patient interaction [6][7][17] - HCTI's subsidiary QuantumNexis has processed over $20 million in revenue through its Ezovion platform, with projections to reach $37 million within six months, indicating an 85% increase [8][9][17] Group 2: Revenue Model Transformation - The upcoming launch of QuantumNexis's integrated payment gateway will create a scalable revenue stream by earning a percentage of all transactions processed through the platform [10][12][17] - This transformation positions HCTI as a hybrid SaaS + fintech company, allowing for recurring transaction-based revenue that scales with platform growth [11][12][17] Group 3: Financial Performance and Market Position - HCTI reported Q2 2025 revenues of $3.6 million, reflecting a 19% year-over-year growth, with a target of approximately $20 million for the full year [14][17] - The company has established strategic partnerships with major industry players such as Amazon AWS, Google Cloud, and Microsoft Azure, enhancing its distribution capabilities and validating its technology [15][17] - Recent contract wins with leading healthcare systems further demonstrate HCTI's market traction and growth potential [15][17] Group 4: Future Growth Pathways - The combination of the Teyame acquisition and QuantumNexis's revenue growth creates multiple expansion pathways for HCTI, appealing to diverse institutional investors [13][17][19] - The acquisition provides immediate access to high-growth international markets, including Europe, the Middle East, Asia-Pacific, and Latin America [17][19] - HCTI's technology integration with Teyame's AI capabilities enhances its existing platforms, creating powerful network effects and cross-selling opportunities [17][19]

PLEASANTON, CA / ACCESS Newswire / October 10, 2025 / Some companies tiptoe into innovation. Healthcare Triangle Inc. (NASDAQ: HCTI ) prefers to kick the door down. ...

Key Points - Several biotech stocks experienced notable after-hours gains on October 9, driven by new data and corporate developments [1] Company Summaries Palisade Bio Inc. (PALI) - Shares traded at $2.26 in after-hours, reflecting a 7.62% gain from the prior close of $2.10, which was up 5% on the day [1] - The company cancelled its special meeting of stockholders due to lack of quorum, withdrawing all proposals from consideration [2] Healthcare Triangle Inc. (HCTI) - Shares traded at $2.88 in after-hours, up 4.35% from the regular session close of $2.76, which was down 17.86% [3] - The company signed a non-binding Letter of Intent to acquire Teyame.AI, projected to generate $34 million in revenue for fiscal year 2025 [4] Nutriband Inc. (NTRB) - Shares traded at $8.25 in after-hours, up 4.30% from the regular session close of $7.91, which was down 6.94% [5] - The company filed a provisional patent application with the USPTO to strengthen its intellectual property for its AVERSA abuse deterrent transdermal [5] Karyopharm Therapeutics Inc. (KPTI) - Shares traded at $6.08 in after-hours, up 4.46% from the regular session close of $5.82, which had declined 1.36% [6] - The company announced financing transactions expected to provide $100 million in financial flexibility, extending its cash runway into Q2 2026 [6] Editas Medicine Inc. (EDIT) - Shares traded at $4.22 in after-hours, up 3.43% from the regular session close of $4.08, which was down 1.69% [7] - The company presented new preclinical proof-of-concept data for its therapy EDIT-401, showing a 90% LDL-C reduction in non-human primates and mice [7] CG Oncology Inc. (CGON) - Shares traded at $45.40 in after-hours, up 2.11% from the regular session close of $44.46, which gained 9.21% [8] - No official news releases or filings were issued during the day [8]

Core Points - Healthcare Triangle, Inc. (HCTI) has entered into warrant exercise agreements with accredited and institutional investors to exercise existing warrants for a total of 239,051 shares of common stock, generating approximately $478,000 in gross cash proceeds [1][2] - The existing warrants' exercise price has been reduced from $20.92 to $2.00 per share, and the new warrants will have an exercise price of $3.00 per share, with a five-year expiration from the date of issuance [1][2] Financial Details - The gross proceeds from the warrant inducement are expected to be around $478,000, excluding any potential proceeds from the exercise of the new warrants and before deducting financial advisor fees and other expenses [2] - The closing of the offering is anticipated to occur on or about October 8, 2025, subject to customary closing conditions [2]